Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CPRX 
Catalyst Pharmaceuticals Inc (CPRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CPRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $34.29
1 Year Target Price $34.29
| 6 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.87% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.65B USD | Price to earnings Ratio 13.82 | 1Y Target Price 34.29 |
Price to earnings Ratio 13.82 | 1Y Target Price 34.29 | ||
Volume (30-day avg) 7 | Beta 0.72 | 52 Weeks Range 14.97 - 26.58 | Updated Date 06/30/2025 |
52 Weeks Range 14.97 - 26.58 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 36.91% | Operating Margin (TTM) 44.81% |
Management Effectiveness
Return on Assets (TTM) 18.59% | Return on Equity (TTM) 29.11% |
Valuation
Trailing PE 13.82 | Forward PE 11.7 | Enterprise Value 2069295798 | Price to Sales(TTM) 4.95 |
Enterprise Value 2069295798 | Price to Sales(TTM) 4.95 | ||
Enterprise Value to Revenue 3.87 | Enterprise Value to EBITDA 7.69 | Shares Outstanding 121975000 | Shares Floating 114600534 |
Shares Outstanding 121975000 | Shares Floating 114600534 | ||
Percent Insiders 6.22 | Percent Institutions 83.28 |
Analyst Ratings
Rating 3 | Target Price 34.29 | Buy 1 | Strong Buy 6 |
Buy 1 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Catalyst Pharmaceuticals Inc
Company Overview
History and Background
Catalyst Pharmaceuticals, Inc. was founded in 2002. It focuses on developing and commercializing therapies for rare neurological diseases and disorders. A significant milestone was the approval of Firdapse for Lambert-Eaton Myasthenic Syndrome (LEMS).
Core Business Areas
- Neurology: Focuses on the development and commercialization of treatments for rare neurological diseases.
Leadership and Structure
The leadership team includes Patrick J. McEneny as Chairman and a team of executives overseeing research, development, and commercial operations. The organizational structure is typical of a pharmaceutical company, with departments focused on R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Firdapse (amifampridine): Firdapse is a treatment for Lambert-Eaton Myasthenic Syndrome (LEMS). Revenue is heavily reliant on Firdapse sales. Competitors include generic versions of amifampridine in some markets. Estimated 80% market share within LEMS treatment, before Ruzurgi. Ruzurgi is a phosphate salt version of amifampridine.
- Ruzurgi (amifampridine): Ruzurgi, also containing amifampridine, is approved for pediatric LEMS. Market share smaller than Firdapse as it caters specifically to the smaller pediatric LEMS population. Competitors include Firdapse itself, as well as generic amifampridine (where available).
Market Dynamics
Industry Overview
The pharmaceutical industry for rare diseases is characterized by high research and development costs, regulatory hurdles, and potential for high returns due to limited competition. The need for specialized treatments and high unmet medical needs are pushing the industry forward.
Positioning
Catalyst Pharmaceuticals is positioned as a leader in developing and commercializing therapies for rare neurological diseases, particularly LEMS. Their competitive advantage lies in their proprietary formulations and established market presence.
Total Addressable Market (TAM)
The total addressable market for LEMS and related neurological disorders is estimated to be in the hundreds of millions annually. Catalyst is positioning itself to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Approved therapies for rare diseases
- Strong market share in LEMS treatment
- Experienced management team
- Proprietary formulations
Weaknesses
- Reliance on a limited number of products
- Potential for generic competition
- Dependence on single drug amifampridine
- Litigation risks from Ruzurgi dispute
Opportunities
- Expansion into new rare disease markets
- Development of new therapies for neurological disorders
- Potential acquisitions of complementary assets
- Geographic expansion into new markets
Threats
- Regulatory challenges
- Generic competition for Firdapse and Ruzurgi
- Pricing pressures
- Unsuccessful clinical trials for new therapies
Competitors and Market Share
Key Competitors
- Jacobus Pharmaceutical (Private)
- AgaMatrix (Private)
Competitive Landscape
Catalyst has a strong position in the LEMS market due to its early entry and successful commercialization of Firdapse. However, competition from generic versions and other treatments could impact future market share.
Growth Trajectory and Initiatives
Historical Growth: Catalyst has experienced significant growth in recent years driven by the commercial success of Firdapse.
Future Projections: Analyst estimates project continued revenue growth based on increasing adoption of Firdapse and potential new product launches.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts for Firdapse and pursuing clinical trials for new indications.
Summary
Catalyst Pharmaceuticals shows robust financial performance and market dominance in treating LEMS. Its reliance on a single drug poses a risk, yet its strategic moves hint at expansion and sustained growth. Future regulatory landscapes and rising competition are areas to watch. Overall, Catalyst presents a mixed profile of strength and vulnerability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Investor Relations
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is estimated and may vary. Financial data is based on the most recently available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Catalyst Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Coral Gables, FL, United States | ||
IPO Launch date 2006-11-08 | President, CEO & Director Mr. Richard John Daly M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 181 | Website https://catalystpharma.com |
Full time employees 181 | Website https://catalystpharma.com | ||
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.